Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05067257
Trial Phases:	Phase II	Protocol IDs:	RTX-CAP-201 (primary) NCI-2022-04731
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Sorrento Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05067257

Summary

This Phase 2 study assesses the safety and efficacy of a single injection of Resiniferatoxin
versus placebo for the treatment of intractable advanced cancer pain.

Objectives

This is a global multicenter, randomized Phase 2 study for subjects with advanced cancer
experiencing intractable pain to assess the safety and efficacy of a single epidural
injection of Resiniferatoxin versus vehicle control. Additional subjects who elect to not
enroll but are willing to be followed will comprise a Concurrent Control Group. Subjects will
be followed for twelve months.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.